| Walgreens #11594 | |
| 110 Hospital Rd, Ste 100, Dares Beach, Maryland 20678 | |
| (410) 535-3838 |
| Name | Walgreens #11594 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 110 Hospital Rd, Ste 100, Dares Beach, Maryland 20678 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (410) 535-3838 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
New research in the July 2021 issue of JNCCN-Journal of the National Comprehensive Cancer Network indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States.
Ikaria, Inc. announced today that its INOMAX® DS drug-delivery systems in the United States are being voluntarily recalled due to the potential failure of a pressure switch which may have an impact on the administration of INOMAX® (nitric oxide) for inhalation to patients. This potential failure was identified by Ikaria as part of its ongoing quality monitoring and review processes. This class I recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). All INOMAX DS systems in Canada also are being voluntarily recalled.
Giving physicians cash payments for reduced hospital spending can help control costs without sacrificing quality or access to care, researchers report in a study released today in the May/June 2008 issue of the journal Health Affairs. The issue is a thematic volume on health reform supported by a grant from the Robert Wood Johnson Foundation.
Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.
› Verified 8 days ago
| NPI Number | 1760694228 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #11594 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 110 Hospital Rd Ste 100, Prince Frederick, MD 20678 |
| Phone Number | 410-535-3838 |
News Archive
New research in the July 2021 issue of JNCCN-Journal of the National Comprehensive Cancer Network indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States.
Ikaria, Inc. announced today that its INOMAX® DS drug-delivery systems in the United States are being voluntarily recalled due to the potential failure of a pressure switch which may have an impact on the administration of INOMAX® (nitric oxide) for inhalation to patients. This potential failure was identified by Ikaria as part of its ongoing quality monitoring and review processes. This class I recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). All INOMAX DS systems in Canada also are being voluntarily recalled.
Giving physicians cash payments for reduced hospital spending can help control costs without sacrificing quality or access to care, researchers report in a study released today in the May/June 2008 issue of the journal Health Affairs. The issue is a thematic volume on health reform supported by a grant from the Robert Wood Johnson Foundation.
Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.
› Verified 8 days ago
| NPI Number | 1962257758 |
| Organization Name | WALGREEN CO. |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 110 Hospital Rd Ste 100, Prince Frederick, MD 20678 |
| Phone Number | 410-535-3838 |
News Archive
New research in the July 2021 issue of JNCCN-Journal of the National Comprehensive Cancer Network indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States.
Ikaria, Inc. announced today that its INOMAX® DS drug-delivery systems in the United States are being voluntarily recalled due to the potential failure of a pressure switch which may have an impact on the administration of INOMAX® (nitric oxide) for inhalation to patients. This potential failure was identified by Ikaria as part of its ongoing quality monitoring and review processes. This class I recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). All INOMAX DS systems in Canada also are being voluntarily recalled.
Giving physicians cash payments for reduced hospital spending can help control costs without sacrificing quality or access to care, researchers report in a study released today in the May/June 2008 issue of the journal Health Affairs. The issue is a thematic volume on health reform supported by a grant from the Robert Wood Johnson Foundation.
Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.
› Verified 8 days ago
News Archive
New research in the July 2021 issue of JNCCN-Journal of the National Comprehensive Cancer Network indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States.
Ikaria, Inc. announced today that its INOMAX® DS drug-delivery systems in the United States are being voluntarily recalled due to the potential failure of a pressure switch which may have an impact on the administration of INOMAX® (nitric oxide) for inhalation to patients. This potential failure was identified by Ikaria as part of its ongoing quality monitoring and review processes. This class I recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). All INOMAX DS systems in Canada also are being voluntarily recalled.
Giving physicians cash payments for reduced hospital spending can help control costs without sacrificing quality or access to care, researchers report in a study released today in the May/June 2008 issue of the journal Health Affairs. The issue is a thematic volume on health reform supported by a grant from the Robert Wood Johnson Foundation.
Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.
› Verified 8 days ago
Walgreens #11594 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 110 Hospital Rd, Dares Beach, Maryland 20678 Phone: (410) 535-3838 |